BOTHELL, Wash., May 29, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that a recent virology study showed its novel, broad-spectrum influenza PB2 inhibitor CC-42344 exhibits ...
Phase 2 Interim Virology Results Indicate Rapid and Sustained Antiviral Activity Against SARS-CoV-2 in Patients with COVID-19 in the Hospitalized Setting AT-527 is Being Studied in Multiple Clinical ...
A Wuhan Institute of Virology study describes assembling part of a monkeypox viral genome for use in a diagnostic test. Although the researchers only made a fraction of the genome — and it matches a ...
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses the spike antigens on its surface to mediate host cell attachment and entry. A new Virology journal study shows that the ...
For individuals with compromised immune systems, chronic infections can be deadly. Thanks to a nearly $2 million grant, a professor in the Virginia-Maryland Regional College of Veterinary Medicine ...
World-leading challenge study expertise helping deliver scalable, high-quality outpatient vaccine trials in healthy ...
CC-42344 was shown to be highly active against the highly pathogenic 2024 Texas H5N1 avian influenza strain The Company’s virology study further confirmed the previous structural and in vitro data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback